Meeting Impression: PCSK9 inhibition at ESC 2016
PCSK9 INHIBITION IN CLINICAL LIPID MANAGEMENT: A CRITICAL REVIEW OF EVIDENCE AND OPPORTUNITIESOct. 2, 2016
This Meeting Impression provides an overview of a satellite symposium organized by PACE-CME during ESC 2016 in Rome, in which the role of PCSK9 proteins in cardiovascular disease was discussed, as well as the emerging development of clinically potent PCSK9 inhibitors. Research into PCSK9 rapidly progressed and it took only a couple of years from the discovery of PCSK9’s clinical relevance until the evaluation of PCSK9 inhibitors in clinical trials. This symposium covered the developmental process culminating in this novel therapeutic strategy.